Altitude Training: Live High Train Low Science

Altitude Training: Live High, Train Low Science

Author: Hüseyin Akbulut — BSc Sport Sciences (rowing), MSc Marmara University

No performance-enhancement strategy in endurance sport has a more rigorous scientific literature than altitude training, and yet few are as frequently misunderstood in application. The basic principle — that living at altitude stimulates physiological adaptations that improve endurance capacity — has been practiced by elite athletes for six decades, since the Mexico City Olympics of 1968 catalyzed widespread interest by demonstrating that athletes from high-altitude nations had distinct advantages in events lasting more than two minutes. In the half-century since, the mechanisms have been characterized in remarkable detail, the optimal protocols have been progressively refined, and the interaction between altitude and other training variables is now understood well enough to generate practical, individualized recommendations. This article examines the science of altitude training with the precision that athletes and coaches deserve.

The Hypoxic Stimulus: Molecular Mechanism

At altitude, the partial pressure of oxygen in inspired air (PiO₂) falls proportionally with barometric pressure. At 2,500 metres, PiO₂ is approximately 74% of sea-level values; at 3,000 metres, approximately 70%. This reduction means that, for any given ventilation rate, the blood leaving the lungs (arterial blood) carries less oxygen. Arterial oxygen saturation falls — typically from 97–98% at sea level to 93–95% at 2,500 metres in acclimatized individuals, with more acute drops of 90% or lower immediately upon ascent.

The cellular response to this oxygen deficit is mediated primarily by HIF-1α (Hypoxia-Inducible Factor-1 alpha), a transcription factor that functions as the master regulator of the hypoxic response. HIF-1α is continuously synthesized in cells but, at normal oxygen levels, is continuously hydroxylated by prolyl hydroxylase enzymes and targeted for rapid proteasomal degradation. When oxygen falls below a threshold, prolyl hydroxylase activity is insufficient to maintain rapid HIF-1α destruction — the protein accumulates and activates its target genes.

Among HIF-1α’s key target genes is erythropoietin (EPO), expressed primarily in interstitial cells of the renal cortex. EPO is a glycoprotein hormone that stimulates proliferation and differentiation of erythroid progenitor cells in the bone marrow, ultimately increasing the number of circulating red blood cells and thereby the oxygen-carrying capacity of blood. This is the primary mechanism through which altitude adaptation improves endurance performance: more red blood cells, more hemoglobin, more oxygen per unit of cardiac output.

The Live High, Train Low Concept: Origins and Evidence

The insight that living at altitude is not the same thing as training at altitude — and that conflating them produces suboptimal results — is the foundational contribution of Ben Levine and Jim Stray-Gundersen’s research program. Their problem statement was straightforward: altitude training camps had been practiced for decades, yet results were inconsistent and the performance gains were sometimes disappointing. Why?

The answer lay in the competing effects of altitude on training quality. Altitude impairs training quality in several ways: at 2,500 metres, the same running speed as at sea level requires approximately 5–8% more physiological effort. Athletes who attempt to maintain sea-level training intensities at altitude are training at higher physiological loads relative to their capacity, which increases injury risk, disrupts sleep (through hypoxic ventilatory response), and may compromise training adaptation. Conversely, athletes who reduce intensity appropriately maintain lower absolute training quality.

The LHTL solution: sleep and live at sufficient altitude to generate the hypoxic stimulus (typically 2,200–2,800 metres for optimal EPO response), but commute or travel to lower altitude (below 1,200 metres) for key training sessions. The 1997 Levine and Stray-Gundersen paper directly tested this: three groups of competitive runners were randomized to LHTL (living at 2,500 m, training at 1,250 m), live high-train high (living and training at 2,500 m), or sea-level control. The LHTL group significantly improved 5000m performance, VO2max, and red cell mass; the live high-train high group improved red cell mass but not performance as substantially; the controls showed no change. This paper established LHTL as the gold standard of altitude training strategy.

EPO Timeline and Hemoglobin Mass Kinetics

The kinetics of the EPO and erythropoietic response to altitude are now well-characterized. Serum EPO begins rising within 6–12 hours of ascent to meaningful altitude, typically peaking between 24–48 hours at values 2–3 times above sea-level baseline. This elevation is maintained throughout altitude residence, though the degree of elevation diminishes as acclimatization progresses and arterial oxygen saturation partially recovers.

Elevated EPO stimulates bone marrow erythropoiesis, but the production of new red blood cells and their maturation requires time. Reticulocytes (immature red blood cells) appear in circulation 4–5 days after EPO elevation begins. Measurable increases in hemoglobin mass require 2–3 weeks of sustained altitude residence; the full adaptive increment — typically 4–8% in well-trained athletes at 2,200–2,800 metres — requires 3–4 weeks.

The practical implication: altitude camps of less than 3 weeks produce incomplete hemoglobin mass adaptation. Some coaches have experimented with protocols as short as 12–14 days, but these are unlikely to achieve the full erythropoietic benefit. The dose-response relationship between altitude duration (up to approximately 28–35 days) and hemoglobin mass gain is approximately linear, after which the marginal gain per additional day diminishes.

Optimal Altitude: Finding the Sweet Spot

The relationship between altitude and EPO response is not linear across all elevations. Below approximately 2,000 metres, the hypoxic stimulus is generally insufficient to produce meaningful EPO elevation. Above approximately 3,000 metres, the hypoxic stress is so great that the quality of both sleep and training is seriously impaired, and the risk of acute mountain sickness and other altitude illness increases substantially.

The “sweet spot” for LHTL is generally regarded as 2,200–2,800 metres for sleeping altitude. At this range, arterial oxygen saturation falls enough to meaningfully activate HIF-1α and EPO expression, sleep quality is manageable (though disrupted compared to sea level), and the logistical challenges of accessing lower-altitude training venues are tractable. The Kenyan training centers around Iten (2,400 m), the Ethiopian Bekoji (2,800 m), and the American training center at Mammoth Lakes (2,439 m) all fall within this optimal range.

Individual Response Variability: The Responder Problem

One of the most significant practical complications in altitude training is the substantial individual variability in response. Not all athletes respond equally to altitude exposure, even when the protocol is identical. Studies consistently identify “high responders” — typically 25–30% of athletes — who show large EPO and hemoglobin mass increases; “low responders” who show minimal changes despite adequate altitude exposure; and the majority of athletes who show intermediate responses.

Identifying individual response patterns prospectively is a goal of ongoing research. Some evidence suggests that baseline ferritin status is predictive: athletes with adequate iron stores (ferritin above 35–40 μg/L) respond more robustly to altitude-induced EPO stimulation, likely because iron availability is rate-limiting for hemoglobin synthesis. Athletes with marginal iron status may have ample EPO signaling but limited iron for new hemoglobin production. Iron supplementation in iron-marginal athletes before altitude camps appears to improve their erythropoietic response.

Real Altitude versus Simulated Altitude

Hypoxic tents and rooms — which reduce the oxygen fraction of delivered air to simulate altitude — offer a potentially convenient alternative to real altitude camps. The technology is commercially available and has been used by elite athletes since the early 2000s. WADA permits their use. The physiological question is whether simulated altitude produces equivalent adaptations to real altitude at the same nominal altitude.

The evidence is mixed. Most well-controlled studies find that normobaric hypoxia (simulated altitude, normal atmospheric pressure) produces qualitatively similar EPO and hemoglobin mass adaptations to hypobaric hypoxia (real altitude, reduced atmospheric pressure), provided the hypoxic dose is matched. However, some research suggests that real altitude may confer additional non-erythropoietic benefits — through the interaction of reduced pressure with other physiological systems — that simulated altitude does not fully replicate. The debate continues, but the practical consensus is that simulated altitude produces meaningful adaptations and is a useful tool for athletes who cannot access real altitude environments.

Post-Altitude Performance: Timing the Return

The timing of sea-level return relative to competition is a major practical decision in altitude training planning, and the science gives a somewhat unsatisfying answer: it depends. Two competing effects occur upon return from altitude. First, a rapid plasma volume restoration (plasma volume falls at altitude due to diuresis; it rebounds quickly at sea level), which temporarily dilutes the elevated red cell mass and may reduce hemoglobin concentration in the first few days. Second, the elevated red cell mass and hemoglobin persists for 2–4 weeks before declining as the EPO stimulus is removed.

The net effect on performance is variable: some athletes perform best within the first 2–4 days of return (before plasma volume fully restores), others 2–3 weeks later. Empirical observation and athlete-specific data from multiple altitude camps is currently the best guide. Athletes who track hemoglobin concentration across multiple altitude cycles can develop a personalized profile of their return response and plan competition timing accordingly.

Conclusion

Altitude training is the best-evidenced non-pharmacological performance enhancement strategy available to endurance athletes — a distinction worth noting in an era of many performance claims. The mechanisms are understood at the molecular level. The optimal protocols are well-characterized. The individual variability is real and manageable with appropriate monitoring. The LHTL strategy, properly implemented, produces hemoglobin mass gains that translate to measurable sea-level performance improvements in the large majority of appropriately selected athletes.

For a comprehensive treatment of altitude training physiology, hemoglobin mass science, EPO dynamics, heat acclimatization, and the complete physiology of endurance performance in extreme environments, see THRESHOLD — a 540-page evidence-based guide to the science of endurance sport.

Learn more about THRESHOLD →